1. Home
  2. RAND vs RFL Comparison

RAND vs RFL Comparison

Compare RAND & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$16.31

Market Cap

41.2M

Sector

Finance

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.23

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
RFL
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Real Estate
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
41.2M
54.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RAND
RFL
Price
$16.31
$1.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.7K
143.0K
Earning Date
11-07-2025
12-11-2025
Dividend Yield
7.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,327,287.00
$1,029,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.63
52 Week Low
$13.25
$1.17
52 Week High
$31.89
$3.19

Technical Indicators

Market Signals
Indicator
RAND
RFL
Relative Strength Index (RSI) 67.10 43.01
Support Level $15.65 $1.21
Resistance Level $17.49 $1.60
Average True Range (ATR) 0.60 0.11
MACD 0.25 0.00
Stochastic Oscillator 72.17 13.95

Price Performance

Historical Comparison
RAND
RFL

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: